Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation

AbstractExon 18 delE709_T710insD is an extremely rare mutation inepidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC); the efficacy of EGFR tyrosine kinase inhibitors against this mutation remains unclear. In this case report, we report a case of NSCLC harboringEGFR exon 18 delE709_T710insD that was not detected by a commercially available assay, but was detected by a next-generation sequencing cancer panel. A 56-year old female patient with advanced NSCLC was diagnosed asEGFR-mutation-negative using the PNAClamp method.ALK rearrangement was also absent and she received cytotoxic chemotherapies. Clinical characteristics, including adenocarcinoma histology and no history of smoking, implied the presence of a driver mutation, so a next-generation-sequencing Oncomine ® Cancer Research Panel was conducted in the patient’s clinical course and theEGFR exon 18 delE709_T710insD mutation was detected. The patient started afatinib as sixth-line treatment and her pulmonary lesion significantly decreased in size. Afatinib was continued for 7 months until disease progressed.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research